Next Article in Journal
The Role of Tumor Microenvironment in Triple-Negative Breast Cancer and Its Therapeutic Targeting
Previous Article in Journal
Development, Functional Characterization, and Matrix Effectors Dynamics in 3D Spheroids of Triple-Negative Breast Cancer Cells
Previous Article in Special Issue
Mechanisms of Corneal Nerve Regeneration: Examining Molecular Regulators
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Targeting Diabetic Retinopathy with Human iPSC-Derived Vascular Reparative Cells in a Type 2 Diabetes Model

1
Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA
2
Schepens Eye Research Institute, Harvard Medical School, and Massachusetts General Hospital, Boston, MA 02114, USA
3
Department of Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
4
Department of Surgery, Indiana Center for Regenerative Medicine and Engineering, Indiana University School of Medicine, Indianapolis, IN 46202, USA
5
Department of Hematology & Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Cells 2025, 14(17), 1352; https://doi.org/10.3390/cells14171352 (registering DOI)
Submission received: 22 July 2025 / Revised: 20 August 2025 / Accepted: 26 August 2025 / Published: 30 August 2025

Abstract

Purpose: To investigate the therapeutic potential of inducible pluripotent stem cell (hiPSC)-based vascular repair, we evaluated two vascular reparative cell populations, CD34+ cells derived from hiPSC (hiPSC-CD34+) and endothelial colony forming cells (ECFCs) derived from hiPSC (iPS-ECFCs), alone and in combination, in a type 2 diabetic (db/db) mouse model of DR. Methods: hiPSC-CD34+ cells (1 × 104) or iPSC- ECFCs (1 × 105) alone or in combination (1.1 × 105) were injected into the vitreous of immunosuppressed db/db mice with six months of established diabetes. One month post-injection, mice underwent electroretinography (ERG) and optical coherence tomography (OCT) to evaluate functional and structural retinal recovery with iPSC administration. Immunohistochemistry (IHC) was used to assess recruitment and incorporation of cells into the retinal vasculature. Retinas from the experimental groups were analyzed using Functional Proteomics via Reverse Phase Protein Array (RPPA). Results: Functional assessment via ERG demonstrated significant improvements in retinal response in the diabetic cohorts treated with either hiPSC-derived CD34+ cells or hiPSC-ECFCs. Retinal thickness, assessed by OCT, was restored to near-nondiabetic levels in mice treated with hiPSC-CD34+ cells alone and the combination group, whereas hiPSC-ECFCs alone did not significantly affect retinal thickness. One month following intravitreal injection, hiPSC-CD34+ cells were localized to perivascular regions, whereas hiPSC-ECFCs were observed to integrate directly into the retinal vasculature. RPPA analysis revealed interaction-significant changes, and this was interpreted as a combination-specific, non-additive host responses (m6A, PI3K–AKT–mTOR, glycolysis, endothelial junction pathways). Conclusions: The studies support that injection of hiPSC-CD34+ cells and hiPSC-ECFCs, both individually and in combination, showed benefit; however, iPSC combination-specific effects were identified by measurement of retinal thickness and by RPPA.
Keywords: KNA cells; CD34 cells; endothelial colony forming cells; inducible pluripotent stem cells; diabetic retinopathy; vascular repair KNA cells; CD34 cells; endothelial colony forming cells; inducible pluripotent stem cells; diabetic retinopathy; vascular repair

Share and Cite

MDPI and ACS Style

Calzi, S.L.; Chakraborty, D.; Hu, P.; Prasad, R.; Adu-Rutledge, Y.; Vieira, C.; Sheini, F.; Boulton, M.E.; Yoder, M.C.; Cheng, C.; et al. Targeting Diabetic Retinopathy with Human iPSC-Derived Vascular Reparative Cells in a Type 2 Diabetes Model. Cells 2025, 14, 1352. https://doi.org/10.3390/cells14171352

AMA Style

Calzi SL, Chakraborty D, Hu P, Prasad R, Adu-Rutledge Y, Vieira C, Sheini F, Boulton ME, Yoder MC, Cheng C, et al. Targeting Diabetic Retinopathy with Human iPSC-Derived Vascular Reparative Cells in a Type 2 Diabetes Model. Cells. 2025; 14(17):1352. https://doi.org/10.3390/cells14171352

Chicago/Turabian Style

Calzi, Sergio Li, Dibyendu Chakraborty, Ping Hu, Ram Prasad, Yvonne Adu-Rutledge, Cristiano Vieira, Fadeela Sheini, Michael E. Boulton, Mervin C. Yoder, Changde Cheng, and et al. 2025. "Targeting Diabetic Retinopathy with Human iPSC-Derived Vascular Reparative Cells in a Type 2 Diabetes Model" Cells 14, no. 17: 1352. https://doi.org/10.3390/cells14171352

APA Style

Calzi, S. L., Chakraborty, D., Hu, P., Prasad, R., Adu-Rutledge, Y., Vieira, C., Sheini, F., Boulton, M. E., Yoder, M. C., Cheng, C., & Grant, M. B. (2025). Targeting Diabetic Retinopathy with Human iPSC-Derived Vascular Reparative Cells in a Type 2 Diabetes Model. Cells, 14(17), 1352. https://doi.org/10.3390/cells14171352

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop